HER2 and ER are key driving factors of cancer proliferation in breast cancer, and extensive preclinical research has been conducted to explore the crosstalk between the ER and HER2 signaling pathways (Pegram, Jackisch & Johnston, 2023). Here, ESR1 is linked to breast carcinoma.